All Updates

All Updates

icon
Filter
Partnerships
Tempus and TScan Therapeutics partner to develop companion diagnostic test
Precision Medicine
Jul 6, 2023
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Product updates
Funding
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Partnerships
Industry news
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
Precision Medicine

Precision Medicine

Jul 6, 2023

Tempus and TScan Therapeutics partner to develop companion diagnostic test

Partnerships

  • AI-driven bioinformatics company Tempus and TScan Therapeutics are collaborating to develop a companion diagnostic test for T-cell receptor (TCR)-engineered T-cell therapies (TCR-T) used in cancer treatment.

  • The partnership aims to create a screening protocol for TScan's Phase I solid tumor clinical trial, which enables customized mixtures of TCR-Ts to be administered to patients based on tumor antigen positivity and intact HLA expression. Tempus' xT assay, a 648-gene panel, is used to identify patients with HLA loss in the tumor, allowing the selection of appropriate TCR-Ts. The collaboration has the potential to help patients with various solid tumor types by identifying those most likely to respond to TCR-T treatment. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.